NASDAQ:EYPT

Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis

Eyepoint Pharmaceuticals logo
$0.23 -0.03 (-11.81%)
Closing price 03:59 PM Eastern
Extended Trading
$0.24 +0.00 (+2.15%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT)

Advanced

Key Stats

Today's Range
$0.23
▼
$0.27
50-Day Range
$0.23
▼
$4.25
52-Week Range
$0.23
▼
$19.11
Volume
4.93 million shs
Average Volume
10.15 million shs
Market Capitalization
$20.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.85
Consensus Rating
Hold

Company Overview

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments.

The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

Founded as pSivida, the company adopted the EyePoint Pharmaceuticals name in 2018. It is based in Watertown, Massachusetts, and its development and commercial activities are centered on ophthalmology.

AI Generated. May Contain Errors.

Eyepoint Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

EYPT MarketRank™: 
3.229881900575 of 5 stars

Eyepoint Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 268th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eyepoint Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, 9 hold ratings, and 2 sell ratings.

  • Upside Potential

    Eyepoint Pharmaceuticals has a consensus price target of $21.85, representing about 9,277.7% upside from its current price of $0.23.

  • Amount of Analyst Coverage

    Eyepoint Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Eyepoint Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($1.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eyepoint Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eyepoint Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eyepoint Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.47% of the float of Eyepoint Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eyepoint Pharmaceuticals has recently decreased by 48.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Eyepoint Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eyepoint Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Eyepoint Pharmaceuticals has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Eyepoint Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eyepoint Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.13% of the stock of Eyepoint Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eyepoint Pharmaceuticals' insider trading history.
Receive EYPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EYPT Stock News Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
HC Wainwright Issues Pessimistic Estimate for EYPT Earnings
See More Headlines

EYPT Stock Analysis - Frequently Asked Questions

Eyepoint Pharmaceuticals' stock was trading at $18.27 at the start of the year. Since then, EYPT shares have decreased by 98.7% and is now trading at $0.2330.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings data on Thursday, November, 12th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.14. The firm earned $756 thousand during the quarter, compared to the consensus estimate of $231 thousand. Eyepoint Pharmaceuticals had a negative trailing twelve-month return on equity of 168.83% and a negative net margin of 13,281.23%.
Read the conference call transcript
.

Shares of Eyepoint Pharmaceuticals reverse split on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Eyepoint Pharmaceuticals' top institutional shareholders include Aberdeen Group plc (3.54%), State Street Corp (3.45%), Goldman Sachs Group Inc. (0.88%) and Algert Global LLC (0.51%). Insiders that own company stock include Jay S Duker, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine, David R Guyer and Ramiro Ribeiro.
View institutional ownership trends
.

Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Alimera Sciences (ALIM), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

Last Earnings
11/12/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:EYPT
CIK
1314102
Employees
214
Year Founded
1987

Price Target and Rating

High Price Target
$68.00
Low Price Target
$0.50
Potential Upside/Downside
+9,277.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$231.96 million
Net Margins
-13,281.23%
Pretax Margin
-13,275.96%
Return on Equity
-168.83%
Return on Assets
-130.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.30
Quick Ratio
3.25

Sales & Book Value

Annual Sales
$31.37 million
Price / Sales
0.85
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
0.25

Miscellaneous

Outstanding Shares
113,780,000
Free Float
81,789,000
Market Cap
$26.51 million
Optionable
Optionable
Beta
1.84

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:EYPT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners